NTX100 Neuromodulation Therapy Developed to Treat Restless Legs Syndrome (RLS)

Noctrix Health Inc. developed novel wearable restless legs syndrome therapy for the treatment of primary moderate-severe Restless Legs Syndrome (RLS) in adults.

Restless Legs Syndrome (RLS), which is treated using dopaminergic drugs, is a sleeping disorder affecting nearly 10 per cent of adult US population and approximately 3 million people each year. Patients suffering with this RLS nervous system disorder are often reported with painful sensations of tingling and try to move their feet which particularly worsens during evenings and nights.

Dopaminergic drugs consist of high doses and pose a high risk of ‘augmentation’ to treat moderate-severe RLS symptoms.The newly developed wearable NTX100 Neuromodulation therapy enables to target the exact peripheral nerve fibres in a manner that is comfortable to wear to sleep. In addition, the novel therapy aims to be a potential treatment option for millions of people suffering with this RLS disorder.

US Food and Drug Administration (FDA) has approved NTX100 Neuromodulation therapy designed for the treatment of adults with primary moderate-severe Restless Legs Syndrome (RLS) who are refractory to medications.